Predicting CYP3A-mediated midazolam metabolism in critically ill neonates, infants, children and adults with inflammation and organ failure.
Janneke M BrusseeNienke J VetElke H J KrekelsAbraham J ValkenburgÉvelyne M Jacqz-AigrainJoop M A van GervenEleonora L SwartJohannes N van den AnkerDick TibboelMatthijs de HoogSaskia N de WildtCatherijne A J KnibbePublished in: British journal of clinical pharmacology (2017)
The recently published pharmacokinetic model for midazolam, quantifying the influence of maturation, inflammation and organ failure in children, yields unbiased clearance predictions and can therefore be used for dosing instructions in term neonates, children and adults with varying levels of critical illness, including healthy adults, but not for extrapolation to preterm neonates.